A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29

Ad4-PA will be given at 10\^9, 10\^10 and 10\^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29

"Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"